1. Home
  2. PTN vs BOLT Comparison

PTN vs BOLT Comparison

Compare PTN & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PTN
  • BOLT
  • Stock Information
  • Founded
  • PTN 1986
  • BOLT 2015
  • Country
  • PTN United States
  • BOLT United States
  • Employees
  • PTN N/A
  • BOLT N/A
  • Industry
  • PTN Biotechnology: Pharmaceutical Preparations
  • BOLT Biotechnology: Pharmaceutical Preparations
  • Sector
  • PTN Health Care
  • BOLT Health Care
  • Exchange
  • PTN Nasdaq
  • BOLT Nasdaq
  • Market Cap
  • PTN N/A
  • BOLT 16.8M
  • IPO Year
  • PTN 1993
  • BOLT 2021
  • Fundamental
  • Price
  • PTN $0.54
  • BOLT $0.40
  • Analyst Decision
  • PTN Strong Buy
  • BOLT Hold
  • Analyst Count
  • PTN 1
  • BOLT 5
  • Target Price
  • PTN $7.00
  • BOLT $1.13
  • AVG Volume (30 Days)
  • PTN 904.9K
  • BOLT 146.3K
  • Earning Date
  • PTN 05-14-2025
  • BOLT 05-13-2025
  • Dividend Yield
  • PTN N/A
  • BOLT N/A
  • EPS Growth
  • PTN N/A
  • BOLT N/A
  • EPS
  • PTN N/A
  • BOLT N/A
  • Revenue
  • PTN $350,000.00
  • BOLT $7,690,000.00
  • Revenue This Year
  • PTN N/A
  • BOLT N/A
  • Revenue Next Year
  • PTN N/A
  • BOLT $77.45
  • P/E Ratio
  • PTN N/A
  • BOLT N/A
  • Revenue Growth
  • PTN N/A
  • BOLT N/A
  • 52 Week Low
  • PTN $0.46
  • BOLT $0.38
  • 52 Week High
  • PTN $2.88
  • BOLT $1.48
  • Technical
  • Relative Strength Index (RSI)
  • PTN 28.90
  • BOLT 40.42
  • Support Level
  • PTN $0.68
  • BOLT $0.38
  • Resistance Level
  • PTN $0.84
  • BOLT $0.47
  • Average True Range (ATR)
  • PTN 0.08
  • BOLT 0.04
  • MACD
  • PTN -0.02
  • BOLT -0.00
  • Stochastic Oscillator
  • PTN 20.22
  • BOLT 18.81

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

Share on Social Networks: